Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Investors deciding betwixt Lexicon Pharmaceuticals (NASDAQ:LXRX) and Pfizer (NYSE:PFE) look a prime betwixt an emerging high-growth biotech subordinate and an established planetary pharmaceutical titan with monolithic scale.

These 2 companies run astatine other ends of the size spectrum, with 1 focusing connected specialized precision medicine portion the different manages a immense portfolio of vaccines and therapies. This examination explores their caller fiscal wellness and hazard profiles.

The lawsuit for Lexicon Pharmaceuticals

Lexicon Pharmaceuticals operates arsenic a contender among biotech stocks by utilizing cistron subject to make treatments for chronic conditions. The institution chiefly focuses connected its commercialized product, INPEFA, portion licensing its programs to partners similar Viatris for planetary markets. Specific lawsuit attraction information was not disclosed successful caller filings.

In FY 2025, gross reached astir $49.8 million, representing astir 60% maturation implicit the erstwhile year. Despite this improvement, the institution reported a nett nonaccomplishment of $50.3 cardinal for the period.

As of its December 2025 equilibrium sheet, the debt-to-equity ratio was astir 0.6x. This ratio compares full indebtedness to shareholder equity, indicating the grade to which a steadfast relies connected borrowed money.

The lawsuit for Pfizer

Pfizer is simply a planetary biopharmaceutical person that discovers, manufactures, and distributes medicines and vaccines crossed astir 200 countries. With a workforce of astir 75,000 employees, the institution maintains a ascendant beingness successful some developed and emerging markets. Its standard allows it to negociate a monolithic merchandise pipeline simultaneously, though circumstantial large customers are not disclosed successful its filings.

During FY 2025, gross reached astir $62.6 billion, representing a flimsy alteration of astir 1.6% from the anterior year. The institution reported nett income of astir $7.8 billion. This level of profitability resulted successful a nett borderline of adjacent to 12.4%.

Based connected the December 2025 equilibrium sheet, the debt-to-equity ratio was astir 0.8x. Free currency travel for the fiscal twelvemonth was astir $9.1 billion, providing important superior for dividends and research.

Risk illustration examination

Lexicon Pharmaceuticals faces important regulatory risks, peculiarly regarding the support process for candidates specified arsenic ZYNQUISTA for benignant 1 diabetes. The institution besides carries an accumulated shortage of astir $2.0 billion, which whitethorn necessitate further superior raises connected unfavorable terms. Furthermore, a azygous entity, Artal Group, holds astir 35% of the shares, limiting the power of smaller retail shareholders.